Why Arena Pharmaceuticals, Inc. Stock Crashed By 31% in 2014
Sean Williams, The Motley Fool - Motley Fool - Tue Sep 09, 8:45AM CDT
Since the year began, the SPDR S&P Biotech ETF has soared 22%. By comparison, shareholders in Arena Pharmaceuticals have endured a multi-month downtrend, with their stock down 31% year-to-date and underperforming the biotech index by a full...
Critical Alerts For Activision Blizzard, ACADIA Pharmaceuticals, Shutterstock, Lockheed Martin and Orexigen Therapeutics Released By InvestorsObserver
PR Newswire - Wed Sep 03, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ATVI, ACAD, SSTK, LMT and OREX.
Technical Coverage on Biotech Equities - Galena Biopharma, Gilead Sciences, MannKind, Orexigen Therapeutics, and IsoRay
PR Newswire - Wed Sep 03, 8:05AM CDT
The US markets on Tuesday, September 02, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 17,067.56, down 0.18% and the NASDAQ Composite closed at 4,598.19, up 0.39%. The S&P 500 finished the session 0.05% lower at 2,002.28. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 737.75, up 0.02%, with the index gaining 6.88% in the previous three months. Investor-Edge has initiated coverage on the following equities: Galena Biopharma Inc. (NASDAQ: GALE), Gilead Sciences Inc. (NASDAQ: GILD), MannKind Corporation (NASDAQ: MNKD), Orexigen Therapeutics Inc. (NASDAQ: OREX), and IsoRay Inc. (NYSE MKT: ISR). Free research on these five companies can be accessed at:
Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent
PR Newswire - Tue Sep 02, 7:00AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that the U.S. Patent and Trademark Office (PTO) has issued a patent related to NB32, the Company's investigational medication being evaluated for weight loss. NB32 is a fixed-dose combination of naltrexone sustained release (SR) and bupropion SR.
Your September Biotech Back-to-School Calendar
at The Street - Tue Aug 26, 8:50AM CDT
The biotech sector hews close to an academic calendar and September marks the start of the busy, event-filled push into the end of the year.
Orexigen Therapeutics Reports Wider Q2 Loss as Costs Mount - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 8:20AM CDT
Orexigen Therapeutics, Inc. (OREX) reported a net loss of 21 cents per share in the second quarter of 2014.
Orexigen Therapeutics Reports Corporate and Financial Results for the Second Quarter Ended June 30, 2014
PR Newswire - Thu Aug 07, 6:00AM CDT
Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced corporate and financial results for the second quarter ended June 30, 2014.
Critical Alerts For VoxelJet, Google, Orexigen Therapeutics, Illumina, and Activision Blizzard Released By InvestorsObserver
PR Newswire - Tue Aug 05, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for VJET, GOOGL, OREX, ILMN, and ATVI.
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences
PR Newswire - Thu Jul 31, 7:40AM CDT
On Wednesday, July 30, 2014, the NASDAQ Composite ended at 4,462.90, up 0.45%, the Dow Jones Industrial Average finished the day 0.19% lower at 16,880.36, and the S&P 500 closed at 1,970.07, up 0.01%. During the session five out of ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 718.94, up 0.36%, and the index has advanced 2.05% in the last one month. Investor-Edge has initiated coverage on the following equities: IsoRay Inc. (NYSE MKT: ISR), Neurocrine Biosciences Inc. (NASDAQ: NBIX), OPKO Health Inc. (NYSE: OPK), Orexigen Therapeutics Inc. (NASDAQ: OREX), and Gilead Sciences Inc. (NASDAQ: GILD). Free research on these five companies can be accessed at:
Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast
PR Newswire - Thu Jul 31, 7:00AM CDT
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) will announce financial results for the second quarter 2014, on Thursday, August 7, 2014 before markets open. The announcement will be followed by a live webcast and conference call at 8:00 a.m. Eastern time (5:00 a.m. Pacific time).
Orexigen Receives CHMP Day 180 List of Outstanding Issues
PR Newswire - Wed Jul 30, 7:00AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced it has received the Day 180 List of Outstanding Issues (LOI) from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the NB32 Marketing Authorization Application (MAA). NB32 (naltrexone sustained release (SR) / bupropion SR) is an investigational drug candidate being evaluated for weight loss.
The Implications of Obesity as a Disability in Europe
Todd Campbell, The Motley Fool - Motley Fool - Sat Jul 19, 3:13PM CDT
If Europe's top court follows the advice of a key advisor, it may soon label severe obesity as a disability. If it does, pressure may increase in the European Union to approve drugs designed to reduce weight, including compounds developed by Arena...
Trade-Ideas: Orexigen Therapeutics (OREX) Is Today's "Dead Cat Bounce" Stock
at The Street - Fri Jul 18, 9:09AM CDT
Trade-Ideas LLC identified Orexigen Therapeutics (OREX) as a "dead cat bounce" (down big yesterday but up big today) candidate
Anti-Obesity Drugs Market 2014-2020 - Global Strategic Business Report
M2 - Thu Jul 17, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n8gsfc/antiobesity) has announced the addition of the "Anti-Obesity Drugs - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Anti-Obesity Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 33 companies including many key and niche players such as: - Arena Pharmaceuticals, Inc. - GlaxoSmithKline Plc - Novo Nordisk - Orexigen Therapeutics, Inc. - Rhythm Pharmaceuticals Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Competitive Scenario 3. Market Trends, Drivers And Challenges 4. Select Pipeline Drug Candidates 5. Select Scientific Breakthroughs 6. Obesity An Introduction 7. Obesity Treatment 8. Anti-Obesity Drugs An Insight 9. Recent Industry Activity 10. Focus On Select Players 11. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 33 (including Divisions/Subsidiaries 34) - The United States (14) - Japan (4) - Europe (
Arena Pharmaceuticals Inc. Still Down After CEO's Sale
Brian Orelli, The Motley Fool - Motley Fool - Tue Jul 15, 4:00PM CDT
"Week-over-week prescriptions are increasing. We're very excited about that. And we expect those prescriptions to continue to increase as, yet a larger salesforce, goes into the field in the next few weeks." -- Arena Pharmaceuticals CEO Jack...
Critical Alerts For Regeneron Pharmaceuticals, Orexigen Therapeutics, News Corp, BorgWarner, and Michael Kors Released By InvestorsObserver
PR Newswire - Fri Jul 11, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for REGN, OREX, NWSA, BWA, and KORS.
14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014
at The Street - Thu Jul 10, 10:54AM CDT
Healthcare investors (and traders) have had a lot to work with so far this year, and the next six months promises to be equally action packed.
3 Stocks Even Volatility-Loving Nasdaq Investors Hate
Sean Williams, The Motley Fool - Motley Fool - Wed Jul 02, 5:16PM CDT
Another month is in the books for the volatile and highly tech-centric Nasdaq Composite , and surprise, surprise -- it was a positive month! Out of the 21 trading sessions in June, the Nasdaq advanced on two-thirds of all days and gained 3.9% for...
The Next Orphan Drug Multibagger and Future Obesity Champion?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon Jun 30, 5:22PM CDT
The newest kid on the biotech block is Zafgen , which successfully IPO'd this month. Shares popped over 20% on its opening day and have held strong since. Zafgen has a small pipeline, but it does have a drug for Prader-Willi Syndrome, an orphan...
3 Biotech Stocks with Catalysts Incoming: Spectrum, Orexigen, and Avanir
Alexander Maxwell, The Motley Fool - Motley Fool - Fri Jun 27, 4:00PM CDT
With so many FDA decisions coming out in a few months, it is an exciting time for biotech investors. For all three of these stocks -- Spectrum Pharmaceuticals , Orexigen Therapeutics , and Avanir Pharmaceuticals -- obtaining FDA approval will...